Requip Indication:

For the treatment of the signs and symptoms of idiopathic Parkinson's disease. Also used for the treatment of restless legs syndrome.

Requip Mechanism Of Action:

Requip binds the dopamine receptors D3 and D2. Although the precise mechanism of action of ropinirole as a treatment for Parkinson's disease is unknown, it is believed to be related to its ability to stimulate these receptors in the striatum. This conclusion is supported by electrophysiologic studies in animals that have demonstrated that ropinirole influences striatal neuronal firing rates via activation of dopamine receptors in the striatum and the substantia nigra, the site of neurons that send projections to the striatum.

Requip Drug Interactions:

Not Available

Requip Food Interactions:

Not Available

Requip Generic Name:


  • Ropinirol [INN-Spanish]
  • Ropinirole HCl
  • Ropinirole hydrochloride
  • Ropinirolum [INN-Latin]

Drug Type:

Small Molecule; Approved; Investigational


Absolute bioavailability is 55%, indicating a first pass effect. Food does not affect the extent of absorption.

Toxicity (Overdose):

Symptoms of overdose include agitation, chest pain, confusion, drowsiness, facial muscle movements, grogginess, increased jerkiness of movement, symptoms of low blood pressure (dizziness, light-headedness)upon standing, nausea, and vomiting.

Protein Binding:

40% bound to plasma proteins with a blood-to-plasma ratio of 1:1.


Hepatic. Ropinirole is extensively metabolized to inactive metabolites via N -despropylation and hydroxylation pathways, largely by the P450 isoenzyme CYP1A2. N-despropyl ropinirole is the predominant metabolite found in urine (40%), followed by the carboxylic acid metabolite (10%), and the glucuronide of the hydroxy metabolite (10%).

Half Life:

6 hours

Dosage Forms of Requip:

Tablet Oral

Chemical IUPAC Name:


Organisms Affected:

Humans and other mammals

Requip to general, pharmacology

General, pharmacology..
General health